DİSÜLFİRAM SANILDIĞI KADAR MASUM MU? İKİ OLGU BAĞLAMINDA DİSÜLFİRAMIN NÖROLOJİK ETKİLERİNİN GÖZDEN GEÇİRİLMESİ

E. Altıntoprak; G. Malkoçlu; D. İ. Haznedaroğlu; H. Coşkunol

Is Disulfiram Innocent as It is Estimated? / A Review of Disulfiram’s Neurologic Effects in the Context of Two Cases

Authors

E. Altıntoprak Ege Üniversitesi Tıp Fakültesi Psikiyatri Anabilim Dalı Bağımlılık Tedavi Birimi
G. Malkoçlu Ege Üniversitesi Tıp Fakültesi Psikiyatri Anabilim Dalı Bağımlılık Tedavi Birimi
D. İ. Haznedaroğlu Ege Üniversitesi Tıp Fakültesi Psikiyatri Anabilim Dalı Bağımlılık Tedavi Birimi
H. Coşkunol Ege Üniversitesi Tıp Fakültesi Psikiyatri Anabilim Dalı Bağımlılık Tedavi Birimi

Keywords:

Disulfiram

Abstract

Disulfiram (DSF) is an agent that inhibits aldehyde dehydrogenase, one of the enzymes involved in alcohol metabolism. When alcohol is consumed during DSF treatment, acetaldehyde accumulates in the body, resulting in a variety of unpleasant effects. Because of this property, it has been used for approximately fifty years as an agent that promotes abstinence in the treatment of alcohol dependence. The effects of DSF interacting with alcohol are well known to clinicians, and patients are informed about this before starting treatment. However, many serious side effects that occur outside of the interaction of DSF with alcohol and are usually slow to develop can be overlooked. Neurotoxicity is one of these serious side effects. This article presents two cases of foot drop resulting from DSF use. These examples highlight the potentiation of the neurotoxic effects of DSF by the dose of DSF used and polypharmacy, and the neurotoxic effects of DSF and its metabolites are reviewed in light of the literature.

References

Disulfiram: Drug monograph. http://www.mentalhealth.com/drug/p30-a02.html#Head_1 adresinden 15.04.2008 de indirilmiştir.

Suh JJ, Pettinati HM, Kampman KM, O’Brien CP. The status of disulfiram: a half of a century later. J Clin Psychopharmacol. 2006;26: 290-302.

Johnson BA. Update on neuropharmacological tre¬atments for alcoholism: scientific basis and clini¬cal findings. Biochem Pharmacol. 2008; 75: 34-56.

Fleming MF, Mihic SC, and Harris RA. Ethanol. Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 11th Edition, LL Brunton, JS Lazo, KL Parker (Ed), New York. 2006, The McGraw-Hill Companies, p. 603.

Murthy KK. Psychosis during disulfiram therapy for alcoholism. J Indian Med Assoc 1997; 95: 80–1.

Quail M, Karelse RH. Disulfiram psychosis. A case report. S Afr Med J. 1980; 57: 551–2.

Rex HH, Moller-Madsen S. Psychosis due to an overdose of disulfiram (Antabus). Ugeskr Laeger. 1986;148:1679–80.

Ceylan ME, Turkcan A, Mutlu E, Onal O. Ma¬nic episode with psychotic symptoms associated with high dose of disulfiram: a case report. J Clin Psychopharmacol. 2007; 27: 224-225.

Goyer PF, Brown GL, Minichiello MD, Major LF. Mood-altering effects of disulfiram in alcoholics. J Stud Alcohol. 1984; 45: 209–13.

De Sèze J, Caparros-Lefebvre D, Nkenjuo JB, Hurtevent JF, Petit H Acute and reversible myoclonic encephalopathy, extrapyramidal syndrome, polyneuropathy caused by chronic disulfiram poisoning Rev Neurol (Paris). 1995;151: 667-9.

Charles V, Boulvin S, Haven F, Gille M. Wernicke’s encephalopathy associated with chronic disulfiram intoxication Rev Neurol. 2006; 162: 1252-6.

Mesiwala AH, Loeser JD. Bilateral globus pal- lidus infarction secondary to disulfiram ingestion. Pediatric Neurosurgery. 2001; 34: 224.

Daniel DG, Swallows A, Wolff F. Capgras delusion and seizures in association with therapeutic dosages of disulfiram. Southern Medical Journal. 1987; 80: 1577-9.

Li MY, Shen YC. Manic episode with psycho¬sis following a lower than recommended do¬sage regimen of disulfiram. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32: 311-2.

Hansen PE, Corydon L. Optic neuritis and polyneuropathy after treatment with disulfiram (Antabus). Ugeskr Laeger. 1979; 141: 3045.

Orakzai A, Guerin M, Beatty S. Disulfiram-induced transient optic and peripheral neuropathy: a case report. Ir J Med Sci. 2007; 176: 319-21.

Mason NA. Disulfiram-induced hepatitis: case report and review of the literature. DICP 1989; 23: 872-875.

Verge C, Lucena MI, López-Torres E, Puche-Garcia MJ, Fraga E, Romero-Gomez M, Andrade RJ. Adverse hepatic reactions associated with calcium carbimide and disulfiram therapy: is there still a role for these drugs? World J Gastroenterol. 2006; 12: 5078-80.

Viquez OM, Valentine HL, Friedman DB, Olson SJ, Valentine WM. Peripheral nerve protein expression and carbonyl content in N,N-diethlydithiocarbamate myelinopathy. Chem Res Toxicol. 2007; 20: 370-379.

Valentine HL, Amarnath K, Amarnath V, Valentine WM. Dietary copper enhances the peripheral myelinopathy produced by oral pyrrolidine dithiocarbamate. Toxicol Sci. 2006; 89: 485-94.

Bevilacqua JA, Diaz M, Diaz V, Silva C, Fruns M. Disulfiram neuropathy. Report of 3 ca¬ses. Rev Med Chil. 2002; 130: 1037-1047.

Watson CP, Ashby P, Bilbao JM. Disulfiram neu¬ropathy. Can Med Assoc J. 1980; 123: 123-6.

Karamanakos PN, Pappas P, Stephanou P and Marselos M. Differentiation of Disulfiram Effects on Central Catecholamines and Hepatic Ethanol Metabolism. Pharmacology & Toxicology. 2001; 88: 106–110.

Berent S, Albers JW. Neurobehavioral Toxicology: Neuropsychological and Neurological Perspectives. 1.baskı, Taylor & Francis, Incorporated Press; 2005: 453-454.

Filosto M, Tentorio M, Broglio L, Buzio S, Lazzarini C, Pasolini MP, Cotelli MS, Scarpelli M, Mancuso M, Choub A, Padovani A. Disulfiram neuropathy: Two cases of distal axonopathy. Clin Toxicol (Phila). 2008; 46: 314-6.

Vaccari A, Ferraro L, Saba P, Ruiu S, Mocci I, Antonelli T, Tanganelli S. Differential mechanisms in the effects of disulfiram and diethyldithiocarbamate in¬toxication on striatal release and vesicular transport of glutamate. J Pharmacol Exp Ther. 1998; 28: 961-7.

Calviello, G., Filippi, G. M., Toesca, A., Palozza, P., Maggiano, N., Nicuolo, F. D., Serini, S., Azzena, G. B., and Galeotti, T. Repeated exposure to pyrrolidine-dithiocarbamate induces peripheral nerve alterations in rats. Toxicol. Lett. 2005; 158: 61-71.

Tonkin, E. G., Valentine, H. L., Milatovic, D. M., and Valentine, W. M. N,N-Diethyldithiocarbamate produces copper accumulation, lipid peroxidation, and myelin injury in rat peripheral nerve. Toxicol. Sci. 2004; 81: 160-171.

Tonkin EG, Erve JC, Valentine WM Disulfiram produces a non-carbon disulfide-dependent schwannopathy in the rat. J Neuropathol Exp Neurol. 2000; 59: 786-97.

Dimayuga FO, Wang C, Clark JM, Dimayuga ER, Dimayuga VM, Bruce-Keller AJ. SOD1 overexpression alters ROS production and redu¬ces neurotoxic inflammatory signaling in mic¬roglial cells. J Neuroimmunol. 2007; 182: 89-99.

Frisoni GB, Di Monda V. Disulfiram neuropathy: a review (1971-1988) and report of a case. Alcohol Alcohol. 1989; 24: 429-37.

Fuller RK, Branchey L, Brightwell DR, Derman RM et al. Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA.1986;256:1449-55.

Chick J. Safety issues concerning the use of disulfiram in treating alcohol de¬pendence. Drug Saf. 1999 20:427-35.

Is Disulfiram Innocent as It is Estimated? / A Review of Disulfiram’s Neurologic Effects in the Context of Two Cases

Is Disulfiram Innocent as It is Estimated? / A Review of Disulfiram’s Neurologic Effects in the Context of Two Cases

Authors

Keywords:

Abstract

References

Downloads

Published

How to Cite

Issue

Section

License